Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Sanofi’s Allegra down from year-ago launch as stocking declines; competitive China landscape weighs on Mead Johnson; GNC revenue up double digits across segments; Claritin shows life in Merck consumer unit; USANA reports return to Western growth; Nu Skin preps ageLOC weight management launch.
You may also be interested in...
Sales & Earnings In Brief
GSK core OTCs outpace market growth; Sanofi consumer business surges in emerging markets; broad drivers fuel GNC growth; USANA builds bonds in China; bullish Mead Johnson raises outlook; more Sales & Earnings In Brief.
Sales & Earnings In Brief
Record Q2 for Herbalife shatters estimates
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.